Sareum Holdings Plc · LSE:SAR
Sareum — H1 2025 Earnings Presentation
25 slides from Sareum's earnings presentation, Mar 25, 2025
Slide 1: Unaudited Interim Results for the Six Months Ended 31 December 2024
Unaudited Interim Results for the Six Months Ended 31 December 2024 25 March 2025 Dr Stephen Parker, Executive Chairman Dr Tim Mitchell, COO & Co-founder Dr John Reader, CSO & Co-founder
Slide 2: Disclaimer
DISCLAIMER The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have profession
Slide 3: Company overview
Company overview • Sareum is a clinical stage small molecule drug development company developing next generation kinase inhibitors for autoimmune disease and cancer • Strategy is to develop programmes to late preclinical or early clinical stages before licensing or partnering • Deep expertise in kin
Slide 4: Progressing our pipeline
Progressing our pipeline Programme Preclinical Clinical Phase 1 Clinical Phase 2 Clinical Phase 3 Potential Indications TYK2 / JAK1 Psoriasis, RA, Lupus, IBD Autoimmune disease SDC - 1801 Acute respiratory symptoms of viral infections / Covid-19 Cancer immunotherapy SDC - 1802 Cancer Monotherapy SRA
Slide 5: Highlights from the period
Highlights from the period Proprietary pipeline TYK2 / JAK1 SDC-1801: Autoimmune diseases. Initial focus on psoriasis • Completed a Phase 1 clinical study in Australia, investigating the safety and pharmacokinetics of an oral formulation of SDC-1801 in programmes ascending doses administered to heal
Slide 6: TYK2 / JAK1 inhibitor programmes
TYK2 / JAK1 inhibitor programmes Proprietary pipeline
Slide 7: SDC-1801: Summary
SDC-1801: Summary Selectivity profile is a differentiator • Dual inhibition of TYK2 and JAK1 is expected to provide greater efficacy than agents that inhibit either alone in multiple autoimmune diseases • Selectivity for TYK2/JAK1 mitigates non-selective JAK class liabilities related to JAK2 and JAK
Slide 8: SDC-1801: TYK2/JAK1 Inhibitor for Autoimmune Disorders
SDC-1801: TYK2/JAK1 Inhibitor for Autoimmune Disorders Clinical-stage dual TYK2/JAK1 inhibitor • Phase 1 clinical trial completed June 2024 - unblinded data received Q3 2024 • High blood exposure achieved - No Serious Adverse Events due to SDC-1801 • Adverse event profile similar in treatment and pl
Slide 9: Dual TYK2/JAK1 Inhibition is optimal for suppression of cytokines linked to many autoimmune diseases
Dual TYK2/JAK1 Inhibition is optimal for suppression of cytokines linked to many autoimmune diseases ✓ Potential for broad coverage and increased efficacy across several key autoimmune targets ✓ Greater coverage than TYK2 and JAK1 single inhibitors ✓ Reduced toxicity by not targeting JAK2 ✓ Small mo
Slide 10: Dual TYK2/JAK1 inhibition more effective than single TYK2 or dual JAK1/2 inhibition in clinical studies
Dual TYK2/JAK1 inhibition more effective than single TYK2 or dual JAK1/2 inhibition in clinical studies % Patients achieving PASI-75 reduction in psoriasis after 12 weeks Brepocitinib (TYK2/JAK1i) clinical data indicates greater efficacy than deucravacitinib (TYK2i) and/or baricitinib (JAK1/2i) in c
Slide 11: SDC-1801 Human Pharmacokinetic Profile
SDC-1801 Human Pharmacokinetic Profile • Half-life of ~17-20h confirms suitability for once-daily oral dosing • MAD Cohort D – plasma exposure ≈ brepocitinib MAD 100mg QD • Exceeds HWB IFN and IL-12 IC50s throughout dosing period • No haematology or serum creatinine changes observed after 10 days d
Slide 12: Biomarker Data
Biomarker Data • IP-10 (JAK1 / IFNγ signalling) • Dose dependent reductions in IP-10 levels in the MAD cohorts • hsCRP (JAK1 / IL-6 signalling) • Dose dependent reductions in hsCRP levels in the MAD cohorts • IFNα ex-vivo challenge (TYK2/JAK1 signalling) • Dose dependent reductions of pSTAT3+ve and
Slide 13: Differentiation vs brepocitinib
Differentiation vs brepocitinib Brepocitinib clinical dosing is generally at 30-45mg QD • Increased serum creatinine levels observed at 30mg brepocitinib QD and higher • Due to OCT2 (kidney transporter) inhibition • SDC-1801 has greater selectivity vs OCT2 • SDC-1801 shows no effect on serum creatin
Slide 14: 2024 - 2025 Ongoing Studies
2024 - 2025 Ongoing Studies Prepare for “Phase 2 readiness” • Drug substance re-synthesis completing • Further formulation • Improve absorption • Prepare capsule sizes consistent with expected Phase 2 doses • 16 week toxicology – scheduled to commence in May 2025 Expecting to complete Q4 2025 14
Slide 15: SDC-1802: Cancer immunotherapy
SDC-1802: Cancer immunotherapy Immunomodulating molecule that has demonstrated good efficacy in preclinical models of cancer • Further translational and preclinical studies being accelerated using funds from recent share subscriptions • Experience in development of SDC-1801 will aid process developm
Slide 16: Chk1 – SRA737
Chk1 – SRA737 Selective Chk1 kinase inhibitor Once daily oral administration Completed Phase 1/2
Slide 17: SRA737: Targeting cancers
SRA737: Targeting cancers Sareum now controls the programme and is entitled to 63.5% of economic revenues • Originally developed by Sareum in collaboration with several Cancer Research UK-funded organisations • Successfully completed two Phase 1/2 clinical trials, funded by original licence partner,
Slide 18: Clinical Opportunity: Synergy with immune checkpoint blockers
Compelling additional clinical development paths supported by synergistic anti-tumour activity In preclinical models & strong mechanistic rationale Synergy with immune checkpoint blockers in SCLC syngeneic model • Anti PD-(L)1 clinical benefit typically limited to 20-25% of patients • Nonclinical da
Slide 19: Clinical Opportunity: Synergy with PARP inhibitors
Compelling additional clinical development paths supported by synergistic anti-tumour activity In preclinical models & strong mechanistic rationale Synergy with PARP inhibitors in ovarian cancer model • PARPi resistance is an emerging unmet clinical need • Nonclinical data show the combination of SR
Slide 20: SRA737: A clinical-stage development candidate with defined Chk1 mechanism and development plan
SRA737: A clinical-stage development candidate with defined Chk1 mechanism and development plan • SRA737 demonstrates promising clinical activity and is well tolerated alone and in combination with chemotherapy • Strong clinical validation for inhibition of ATR/Chk1 axis; SRA737 is a competitively p
Slide 21: Unaudited Financial Results
Unaudited Financial Results For the period ending 31 December 2024
Slide 22: Income statement
Income statement Restated Unaudited Unaudited Audited Six months ended Six months ended Year ended 31 Dec 24 31 Dec 23 30 Jun 24 £’000 £’000 £’000 Revenue -. -. -. Other operating income 22. Operating expenses (1,346) (2,536) (4,596) Share of profit/(loss) of associate (2) 4. (60) Operating loss (1,
Slide 23: Balance sheet
Balance sheet Restated Unaudited Unaudited Audited As of As of As of 31 Dec 2024 31 Dec 2023 30 Jun 2024 £’000 £’000 £’000 Non-current assets Computers and equipment - - - Investment in associate 7 46 9 7 46 9 Current assets Debtors 553 1,513 1,299 Cash and cash equivalents 4,145 408 1,459 4,698 1,9
Slide 24: 2025 Milestones
2025 Milestones SDC-1801 • Submission of phase I trial paper to peer-reviewed journal • Completion of synthesis & formulation of new drug product for long-term toxicology trials • Long-term toxicology trials completed SDC-1802 • Commencement of manufacture of drug product for formal preclinical tria
Slide 25: Sareum Holdings plc
Sareum Holdings plc Unit 2A, Langford Arch London Road, Pampisford Cambridge CB22 3FX United Kingdom Tel: +44 (0) 1223 497700 Email: info@sareum.com 25